Адрес и телефон

Gender in cardiac resynchronisation therapy

01 окт октября 2019
2019

Background: Introduction: We compared group I (61 men) and group II (16 women) of patients undergoing
CRT. Plasma levels of Nt-proBNP, interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor alpha(TNF-α), C-reactive protein, galectin-3 (Gal-3), metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase 1 and 4 (TIMP-1, TIMP-4), ratio MMP-9/TIMP-1, MMP-9/TIMP-4 were measured.

According to dynamics of left ventricular end-systolic volume patients were classified into non-responders, responders, super-responders. Results: Women more likely had left bundle branch block (81.3 vs 47.5%, P = 0.016), were more super-responders (66.7 vs 30.5%). Both groups showed decrease of IL-6 (P < 0.05), TNF-α (P < 0.001; P < 0.05), NT-proBNP (P = 0.001; P < 0.05), Gal-3 (P < 0.05).

 In women there was decrease of IL-6 by 44.4 vs 23.5% in men (P = 0.029), TNF-α by 41.4 vs 30.9%, NT-proBNP by 73.3 vs 46% (P = 0.002), Gal-3 by 82.3 vs 64.9% (P < 0.05). Group I also showed decrease of IL-10 by 34.2% (P < 0.05). Group dynamics of TIMP-1 was opposite: men showed tendency to reduction of TIMP-1 (P = 0.054), women showed increase of TIMP-1 (P < 0.05). Besides, men showed decrease of MMP-9 (P < 0.05) and ratio MMP-9/TIMP-4 (P < 0.05).

Conclusion: The best response to CRT is associated with female gender explained by greater decrease of neurohormonal activation, systemic inflammation and fibrosis. The revealed opposite dynamics of TIMP-1 in the groups can demonstrate the existence of gender features of matrix metalloproteinase system activity and their tissue inhibitors.


23.07.2020

ЦЕЛИ: Предварительный анализ выявил степень, в которой алирокумаб уменьшал общие (первые и последующие) нефатальные сердечно-сосудистые события и смертность от всех причин в исходах ODYSSEY.

23 Июля 2020
#Статьи
14.02.2020

BACKGROUND:After ACS, alirocumab added to intensive stain therapy favourably impacted on Type l and 2 MIs.

14 Февраля 2020
#Статьи

powered by